Investment
Recent Earnings - May 05, 2026
Editor's Notes: * One interesting idea from the recent earnings is the (mis)pricing of big pharma patent cliffs right now. Take Bristol-Myers Squibb as an example. The market is so terrified of its impending 2028 exclusivity cliff for blockbusters like Opdivo and Eliquis that it has punished